Marché des tests moléculaires au point de service (à l’aide du NAAT) en Asie du Sud-Est – Tendances et prévisions de l’industrie jusqu’en 2028

Analyse et perspectives du marché des tests moléculaires au point de service (à l'aide du NAAT) en Asie du Sud-Est

Le marché des tests moléculaires au point de service (utilisant le NAAT) en Asie du Sud-Est devrait croître en raison de l’amélioration des installations et des infrastructures de soins de santé et de l’adoption de tests au point de service dans les hôpitaux, les laboratoires et les cliniques, ce qui peut stimuler la croissance du marché. Les autres facteurs qui devraient propulser la croissance du marché des tests moléculaires au point de service (utilisant le NAAT) comprennent la prévalence croissante des maladies infectieuses.

D'autres facteurs, tels que le manque de professionnels qualifiés et le coût élevé des tests moléculaires au point de service personnalisés (utilisant le NAAT), freinent la croissance du marché des tests moléculaires au point de service (utilisant le NAAT) en Asie du Sud-Est. D'autre part, l'augmentation des dépenses de santé et l'émergence de pays dotés d'hôpitaux développés constituent une opportunité pour développer le marché des tests moléculaires au point de service (utilisant le NAAT) en Asie du Sud-Est.

Data Bridge Market Research analyse que le marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est connaîtra une croissance de 8,9 % entre 2021 et 2028.

Définition du marché des tests moléculaires au point de service (utilisant le NAAT) en Asie du Sud-Est

POCT is characterized as testing which can be done close to the patient where a medical decision can be made immediately, including the results and monitoring. POCT devices now entering clinical use are based on nucleic acid amplification technologies (NAAT), defined here as second-generation devices. These platforms generally have improved sensitivity, typically 60 to 90%, compared to first-generation POCTs, and require portable instrumentation with a footprint of approximately 30cm x 30cm. These instruments are essentially used in molecularly detecting various disorders such as HIV, HPV, and respiratory disease through NAAT technology. NAAT is Nucleic Acid Amplification Techniques that allow the identification of pathogenic organisms by detecting their DNA or RNA.

In the worldwide pandemic, attempt to synergize the sensitivity of NAATs and the ease of use of POCT assays, miniaturized NAAT-based POCT devices and assays were devised for faster screening and diagnosis of COVID-19, which also propelled the growth of the market.

South East Asia Molecular Point of Care Testing (using NAAT) Market Dynamics

 This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

• INCREASE PREVALENCE OF CHRONIC DISEASES

It is a common fact that health degeneration starts with an increase in age. As the rate of chronic disease grows with time, the factors associated with the disease rates also increase. The high number of obese/ overweight population also has increased the prevalence of chronic diseases in various regions across the globe. The rise in the number of chronic diseases similar to HPV, STI, and TB, among more, has led to people opting for NAAT-based point-of-care and products for testing. Therefore, this will drive the growth of the South East Asia Molecular point of care testing (using NAAT) market in the coming years.

• IMPROVEMENT IN DIAGNOSIS-SEEKING RATE

With the increase in the successful diagnosis of chronic diseases, including cancer, anemia, type 2 diabetes, and others, the improved health care professionals provide regular training sessions for the professionals for conducting tests in account for the improvement of diagnosis rate in the region. With the increase in the burden of diseases, the diagnosis rate is also increasing. With the advancements in the diagnosis, the rate is also growing for people going through the diagnosis.

• RISE IN PREFERENCE FOR HOMECARE TESTING

Home healthcare preferences make clinical information available at the right place and time. It will also help in reducing error and increasing safety with ensured quality. They also help elders in the case of a medical emergency. There have been many strategic changes done in health care to address point-of-care testing benefits. As per the World Health Organization (WHO), the number of people aged 65 and above is expected to rise from an estimated 524 million in 2010 to approximately 1.5 billion in 2050, with developed countries accounting for the majority of the increase.

Opportunities

• STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS

An increase in the burden of chronic and non-chronic disease globally coupled with the rise in the geriatric population in Africa and Asia has created more demand for the development of new kits and solutions for molecular point-of-care testing with better efficacy and less time consumption. To provide diagnosis and screening in this region, the players in the market undergo partnership and agreement with each other to provide quality care through kits and instruments to the South East Asia population.

• RisE Healthcare Expenditure

Increasing healthcare expenditure and infrastructure can help patients take hassle-free advanced treatment to receive better diagnoses, procedures, and treatment for fast recovery. Point-of-care testing devices are beneficial for detecting various diseases and supporting treatment plans using POC software and solutions. Healthcare spending comprises out-of-pocket payments (people paying for their care), government expenditure, and sources including health insurance and activities by non-governmental organizations.

Restraints/Challenges

• HIGH COST OF PRODUCTS

The point-of-care testing products require a substantial considerable cost for the development process. As the concept needs to be locked down, the materials must be sourced, and it is essential to consider lead times. Additionally, the process is time-consuming as the device design needs sufficient time to fully mature before bringing to the market for use.

• LACK OF ALIGNMENT WITH TEST RESULTS OBTAINED FROM LABORATORIES

When compared with the results of laboratory testing standards, the NAAT testing results differ. Laboratory testing is more advanced, follows the process, protocol, and science for laboratory testing, and fully integrates with the technology necessary to analyze, validate, and accurately document effects. However, POCT/NAAT is undoubtedly associated with a lack of precise results. Molecular POCT cannot complete the standardization, and other critical criteria cannot achieve the standardization and different essential standards. It is a significant challenge for the South East Asia Molecular point of care testing market. The PoC tests might sometimes provide erroneous results and suffers test results variability.

Post-COVID-19 Impact on South East Asia Molecular Point of Care Testing (using NAAT) Market

COVID-19 significantly impacted the molecular point of care testing (using NAAT) market. COVID-19 has positively affected the price and demand of molecular point of care testing (using NAAT) products at a higher level because of progressive online sales and technological advancements. The COVID-19 pandemic outbreak positively impacted the market's growth owing to the increased requirement for molecular point of care testing (using NAAT), especially in various hospitals. The current priority in most hospitals is given to COVID-19 treatments as the surge of COVID-19 cases is still persistent, which also increases the usage of molecular point of care testing (using NAAT). Moreover, many international governments and healthcare organizations have supported the supply of these products due to their high priority in crucial cases.

Recent Developments

• In November 2021, F.Hoffmann-La Roche Ltd announced that Roche ranked as one of the top three most sustainable healthcare companies in the Dow Jones Sustainability Indices for the thirteenth year. This increased the business doing capacity and business expansion in the forecast period
• In October 2021, Thermo Fisher Scientific Corporation received FDA approval for the TaqMan COVId-19 test SARS-COV molecular Assay. This increased the product portfolio of the company and contributed to the company revenue in the forecast period

South East Asia Molecular Point of Care Testing (using NAAT) Market Scope

South East Asia molecular point of care testing (using NAAT) market is categorized into five notable segments based on the product, indication, end user, mode of testing, and distribution channel. The growth amongst these segments will help to analyze market growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Instruments
• Consumables and Reagents

Based on product, the South East Asia molecular point of care testing (using NAAT) market is segmented into instruments and consumables and reagents.

Indication

• Sexually Transmitted Infection (STI) Testing
• Respiratory Infection Testing
• Gastrointestinal Tract Infection Testing
• Others

Based on indication, the South East Asia molecular point of care testing (using NAAT) market is segmented into sexually transmitted infection (STI) testing, respiratory infection testing, gastrointestinal tract infection testing, and others.

End User

• Laboratories
• Hospitals
• Clinics
• Ambulatory Centers
• Home Care
• Assisted Living Facilities
• Others

Based on End User, the South East Asia molecular point of care testing (using NAAT) market is segmented into laboratories, hospitals, clinics, ambulatory centers, home care, assisted living facilities, and others.

Mode of Testing

• Prescription-Based Testing
• OTC Testing

Based on testing mode, the South East Asia molecular point of care testing (using NAAT) market is segmented into prescription-based and OTC testing.

Canal de distribution

• Pharmacie de l'hôpital
• Pharmacie de détail
• Pharmacie en ligne

En fonction du canal de distribution, le marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est est segmenté en pharmacie hospitalière, pharmacie de détail et pharmacie en ligne.

Analyse/perspectives régionales du marché des tests moléculaires au point de service (à l'aide du NAAT) en Asie du Sud-Est

Le marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est est analysé. Des informations sur la taille du marché et les tendances sont fournies en fonction du produit, de l'indication, de l'utilisateur final, du mode de test et du canal de distribution.

Le rapport sur le marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est couvre Singapour, le Vietnam, la Thaïlande, la Malaisie, l'Indonésie, les Philippines et le reste de l'Asie du Sud-Est.

Singapour domine le marché des tests moléculaires au point de service (utilisant le NAAT) en Asie du Sud-Est en termes de part de marché et de chiffre d'affaires. Il continuera à accroître sa domination au cours de la période de prévision. Cela est dû à la prévalence croissante des maladies infectieuses et chroniques et aux avancées technologiques croissantes dans le secteur de la santé.

Analyse du paysage concurrentiel et des parts de marché des tests moléculaires au point de service (utilisant le NAAT) en Asie du Sud-Est

Le paysage concurrentiel du marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est fournit des détails sur le concurrent. Les composants inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence en Asie du Sud-Est, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les directives réglementaires, l'analyse de la marque, les approbations de produits, la charge utile du produit, la domination des applications, la courbe de survie technologique. Les points de données ci-dessus fournis ne concernent que les entreprises se concentrant sur le marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est.

Certains des principaux acteurs opérant sur le marché des tests moléculaires au point de service (utilisant NAAT) en Asie du Sud-Est sont Thermo Fisher Scientific Inc., Hologic, Inc., Seegene Inc., SD Biosensor, INC., Sysmex Corporation, Sekisui Diagnostics, Wondfo, F. Hoffmann-La Roche Ltd, bioMérieux SA, Grifols, SA, Danaher et d'autres.

SKU-66924